creatine-ethyl-ester has been researched along with Mental-Retardation--X-Linked* in 2 studies
1 trial(s) available for creatine-ethyl-ester and Mental-Retardation--X-Linked
Article | Year |
---|---|
Response to creatine analogs in fibroblasts and patients with creatine transporter deficiency.
Creatine transporter (CRTR) deficiency is one of the most frequent causes of X-linked mental retardation. The lack of an effective treatment for this disease, in contrast to creatine (Cr) biosynthesis disorders that respond to Cr monohydrate (CM), led us to analyze the efficacy of a lipophilic molecule derived from Cr, creatine ethyl ester (CEE), in fibroblasts and patients with CRTR deficiency. CM and CEE uptake studies were performed in six controls and four fibroblast cell lines from patients. We found a significant increase in Cr uptake after 72 h of incubation with CEE (500 micromol/L) in patients and control fibroblasts compared to incubation with CM. Subsequently, we assayed the clinical effect of CEE administration in four patients with CRTR deficiency. After 1 year of treatment, a lack of significant improvement in neuropsychological assessment or changes in Cr level in brain (1)H MRS was observed, and CEE was discontinued. In conclusion, this 12-month trial with CEE did not increase the brain concentration of Cr. Our in vitro data lend support to the idea of a certain passive transport of CEE in both pathological and control cells, although more lipophilic molecules or other cell systems that mimic the BBB should be used for a better approach to the in vivo system. Topics: Brain; Cell Line; Creatine; Fibroblasts; Humans; Magnetic Resonance Spectroscopy; Membrane Transport Proteins; Mental Retardation, X-Linked; Treatment Outcome | 2010 |
1 other study(ies) available for creatine-ethyl-ester and Mental-Retardation--X-Linked
Article | Year |
---|---|
Di-acetyl creatine ethyl ester, a new creatine derivative for the possible treatment of creatine transporter deficiency.
Creatine is pivotal in energy metabolism of the brain. In primary creatine deficiency syndromes, creatine is missing from the brain. Two of them (AGAT and GAMT deficiency) are due to impaired creatine synthesis, and can be treated by creatine supplementation. By contrast, creatine transporter deficiency cannot be treated by such supplementation, since creatine crossing of biological membranes (plasma membrane and blood-brain barrier) is dependent on its transporter. This problem might be overcome by modifying the creatine molecule to allow it to cross biological membranes independently of its transporter. Thus, we designed and synthesized di-acetyl creatine ethyl ester (DAC), a compound that should cross biological membranes independently of the transporter due to its very high lipophilicity. We investigated its ability to increase intracellular creatine levels even after block of creatine transporter, and to counter cell damage induced by transporter block. In our experiments after block of the creatine transporter, DAC was able both to prevent electrophysiological failure and to increase intracellular creatine. Interestingly, it did so in micromolar concentrations, at variance with all the other creatine derivatives that we know of. Topics: Animals; Brain; Brain Diseases, Metabolic, Inborn; Creatine; Guanidinoacetate N-Methyltransferase; Language Development Disorders; Membrane Transport Proteins; Mental Retardation, X-Linked; Mice; Movement Disorders; Plasma Membrane Neurotransmitter Transport Proteins | 2018 |